Rheumatoid arthritis is a chronic autoimmune disease that causes progressive articular
damage, functional loss, and comorbidity. The development of effective biologics and small …

Antibody deficiency or hypogammaglobulinemia can have primary or secondary etiologies.
Primary antibody deficiency (PAD) is the result of intrinsic genetic defects, whereas …

Despite major progress in the treatment of rheumatoid arthritis (RA), strong unmet medical
need remains, as only a minor proportion of patients reach sustained clinical remission. New …

The clinical success of anti-CD20 monoclonal antibody (mAb)-mediated B cell depletion
therapy has contributed to the understanding of B cells as major players in several …

Objective To investigate the efficacy and safety of ocrelizumab in patients with class III/IV
lupus nephritis (LN). Methods Patients were randomized 1: 1: 1 to receive placebo, 400 mg …

B cells and antibodies account for the most prominent immunodiagnostic feature in patients
with multiple sclerosis (MS), namely oligoclonal bands. Furthermore, evidence is …

Objectives To summarise, by a systematic literature review (SLR), the evidence regarding
pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat …

B cells play a central role in the pathogenesis in multiple sclerosis (MS), being involved in
the activation of proinflammatory T cells, secretion of proinflammatory cytokines, and …

More than 10 disease-modifying therapies (DMT) are approved by the European Medicines
Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of multiple …

Background B cells can contribute to immune-mediated disorders. Targeting CD20 has
proved to be efficacious in several B cell-mediated immunopathologies, as illustrated by the …